Laquinimod

Parent companies: Teva Neuroscience, Inc. and Active Biotech.

Oral medication taken daily.

Studied in relapsing types of MS.

This drug works as an immunomodulator, altering certain processes of the immune system.

Results from a Phase II trial for individuals with RRMS significantly reduced disease activity by 40 percent (as measured by MRI).

Compared to the placebo-treated group, the study showed trends toward: reducing annual relapse rates; more patients were relapse-free during the trial period; time to first relapse was delayed; and the drug was well tolerated.

Initiation of two global Phase III trials for individuals with relapsing MS was announced in June 2007; trials to be conducted in the United States, Europe, and other locations.